Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 3:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HORIZANT 600 mg Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Gabapentin for Pain Management During Dilation and Evacuation

NCT03635905
View directory record Official record
Conditions
Pain
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence

NCT01014533
View directory record Official record
Conditions
Alcohol Dependence, Insomnia
Interventions
Placebo dispensed to subject., Gabapentin dispensed to subject.
Drug
Lead sponsor
Dr. Kirk Brower
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

NCT00777023
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

NCT01411124
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
gabapentin enacarbil, diphenhydramine, placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 18, 2026, 3:12 PM EDT
Withdrawn Phase 3 Interventional

Gabapentin and Chronic Post Surgical Pain

NCT03867240
View directory record Official record
Conditions
Pain, Postoperative, Scoliosis Idiopathic
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 4 Interventional Results available

GRASSP: Gralise® for Spine Surgery Pain

NCT01764464
View directory record Official record
Conditions
Post-laminectomy Pain Syndrome
Interventions
Gralise®, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Control With Total Knee Replacement

NCT01680549
View directory record Official record
Conditions
Postoperative Pain
Interventions
Gabapentin
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
25 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response

NCT01301001
View directory record Official record
Conditions
Vulvodynia
Interventions
Placebo oral capsule, Gabapentin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
New Brunswick, New Jersey • Rochester, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

NCT05319756
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 18, 2026, 3:12 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean Section

NCT03330119
View directory record Official record
Conditions
Pregnancy Related, Narcotic Use
Interventions
Alternate Management, Control
Drug
Lead sponsor
Brest, Norman A., M.D.
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine

NCT01476124
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
morphine Placebo, GEn 600 mg, Morphine, GEn Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00755417
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 2 Interventional Results available

Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans

NCT00654953
View directory record Official record
Conditions
Cocaine Dependence, Depressive Symptoms
Interventions
sertraline, Placebo, gabapentin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gabapentin Regimens and Their Effects on Opioid Consumption

NCT03334903
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Opioid Use, Opioid Dependence
Interventions
Gabapentin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

NCT04570436
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg, diazepam 20 mg, placebo
Drug · Other
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Gabapentin for Perioperative Pain Relief in Surgical Abortion

NCT04292171
View directory record Official record
Conditions
Pain Control
Interventions
Gabapentin, Placebos
Drug
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 18, 2026, 3:12 PM EDT
Not listed Phase 4 Interventional

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

NCT02560766
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg, HORIZANT 600 mg, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Redwood City, California • Gulf Breeze, Florida • Winter Park, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Prometa Protocol for Alcohol Dependence

NCT00262639
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Flumazenil and Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Not applicable Interventional Results available

Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores

NCT02840240
View directory record Official record
Conditions
Pain
Interventions
Gabapentin enacarbil, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 18, 2026, 3:12 PM EDT
Withdrawn Early Phase 1 Interventional

Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension

NCT01441531
View directory record Official record
Conditions
Tourniquet-induced Pain, Tourniquet-induced Hypertension
Interventions
gabapentin 600 mg po, Placebo pill given one hour before surgery
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 4 Interventional Results available

Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

NCT02330094
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Phase 4 Interventional Results available

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

NCT01668667
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 18, 2026, 3:12 PM EDT
Completed Not applicable Interventional Results available

Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women

NCT02040532
View directory record Official record
Conditions
Menopause, Hot Flashes, Vasomotor Disturbance
Interventions
Gabapentin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 18, 2026, 3:12 PM EDT
Terminated Phase 3 Interventional

Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery

NCT04176419
View directory record Official record
Conditions
Postoperative Pain Control, Opioid Consumption
Interventions
Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 18, 2026, 3:12 PM EDT